Neurophth Therapeutics
Wuhan, China· Est.
China's leading ocular gene therapy company developing AAV-based treatments for inherited retinal diseases like LHON.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $950M
AI Company Overview
China's leading ocular gene therapy company developing AAV-based treatments for inherited retinal diseases like LHON.
OphthalmologyRare Diseases
Technology Platform
Adeno-associated virus (AAV) vector platform optimized for intraocular delivery of therapeutic genes to treat inherited and acquired retinal diseases.
Opportunities
First-mover advantage in China's large and underserved market for inherited retinal diseases, with potential to expand its AAV platform to treat more common ophthalmologic conditions like vascular retinopathies and optic nerve injury.
Risk Factors
Clinical and regulatory risk associated with late-stage trials, high cost and reimbursement challenges for gene therapies in China, and potential competition from other global gene therapy companies targeting similar indications.
Competitive Landscape
Primary global competitors include GenSight Biologics (GS010 for LHON) and other gene therapy developers like Spark Therapeutics (now Roche) and Adverum in ophthalmology. Neurophth differentiates through its extensive, long-term IIT data, first-in-China status, and integrated platform.